

Contents

Preface	xxiii
Foreword	xxv
List of Contributors	xxvii

Section I Epilepsy: Epidemiology, Diagnostic Evaluation and Co-Morbidities 1

1	Introduction and Epidemiology 3
	<i>Joseph I. Sirven and Gregory D. Cascino</i>
	Incidence and Prevalence of Epilepsy 3
	Incidence and Prevalence of Acute Symptomatic Seizures 5
	Looking Beyond Epidemiology: The State of Epilepsy
	Care in the United States 6
	Risk Factors for Epilepsy 7
	Conclusion 8
	References 8
2	Classification of Seizures and the Epilepsies 11
	<i>Elaine C. Wirrell</i>
	Introduction 11
	Why Is Classification Important? 11
	Clinical 12
	Epidemiology 12
	Classification Scheme 12
	Level 1: Seizure Types 13
	Focal Onset Seizures 13
	Generalized Onset Seizures 14
	Unknown Onset Seizures 14
	Level 2: Epilepsy Based on Seizure Type 15
	Focal Epilepsy 15
	Generalized Epilepsy 15
	Generalized and Focal Epilepsy 15

	Unknown if Generalized or Focal Epilepsy	15
	Level 3: Epilepsy Syndrome	15
	Determination of Etiology	17
	Specific Etiologies	18
	Genetic	18
	Structural	18
	Metabolic	18
	Immune	18
	Infectious	19
	Unknown	19
	Comorbidities	19
	Epileptic Encephalopathy	19
	Developmental Encephalopathy	19
	Natural History of Epilepsies	20
	References	20
3	Etiology and Pathology of Epilepsy	23
	<i>Katherine C. Nickels and Katherine Noe</i>	
	Introduction	23
	Provoked Seizures	24
	Etiologic Classification of Epilepsy	25
	Genetic	25
	Structural	28
	Infectious	30
	Metabolic	30
	Autoimmune	31
	Summary	32
	References	32
4	Genetics of Epilepsy	37
	<i>Anthony L. Fine, Lily C. Wong-Kiesel and Raj D. Sheth</i>	
	Introduction	37
	Genetic Testing	38
	Genotype-Phenotype correlation	39
	Precision Medicine in Epilepsy Genetics	40
	Selected Genetic Epilepsy Syndromes	41
	Neurocutaneous Disorders	41
	Tuberous Sclerosis Complex (TSC)	41
	Sturge-Weber Syndrome (SWS)	43
	Malformations of Cortical Developments (MCD)	44
	Neurodevelopmental Disorders	46
	Progressive Myoclonic Epilepsies (PME)	46
	Familial Focal Epilepsies	51
	Autosomal Dominant Sleep-Related Hypermotor Epilepsy (ADSHE)	51

Autosomal Dominant Focal Epilepsy with Auditory Features	51
GRIN2A and CSWS/Landau–Kleffner Syndrome	54
Conclusion	54
References	54

5 **Burden of Epilepsy** 63

J. Layne Moore, Amy Z. Crepeau and Gregory D. Cascino

Introduction	63
Psychosocial Considerations	63
Psychological Distress	64
Stigma	64
Cognitive Effects	65
Behavioral Risk Factors	65
Smoking	65
Health and Disability	66
Morbidity	66
Economic Costs	67
Employment	68
Driving	69
Impact of Treatment with Antiseizure Drugs	70
Conclusion	70
References	70

6 **EEG and Epilepsy** 77

Anteneh M. Feyissa, Gregory A. Worrell and Terrence D. Lagerlund

Introduction	77
Types and Techniques of Recording	78
Routine Scalp EEG	78
Prolonged Video EEG Monitoring	80
Methods of Recording	80
Activation Procedures	81
Artifacts	82
Interictal EEG	82
Focal Interictal Epileptiform Discharges	84
Generalized Interictal Epileptiform Discharges	85
Clinical Utility of Interictal Epileptogenic Discharges	86
Ictal EEG Findings in Epilepsy	88
Focal Epilepsy	88
Generalized Epilepsy	89
EEG Source Localization and Epilepsy	90
The Forward Problem	90
The Inverse Problem	91
MEG and Source Localization and Epilepsy	93
Conclusion	94
References	95

7	Neuroimaging in Epilepsy	99
	<i>Benjamin H. Brinkmann, Elson L. So, Robert E. Watson and Amy L. Kotsenas</i>	
	Introduction	99
	Computerized Tomography (CT)	99
	Magnetic Resonance Imaging (MRI)	100
	MRI Safety Consideration with Implanted Devices	102
	7 T MRI	102
	Positron Emission Tomography (PET)	102
	Single Photon Emission Computed Tomography (SPECT)	105
	Functional Magnetic Resonance Imaging (fMRI)	107
	Image Processing	108
	Conclusion	110
	References	111
8	The Evaluation of Nonepileptic Paroxysmal Events	117
	<i>Sara Dawit and Joseph F. Dratzkowski</i>	
	Introduction	117
	Syncope	119
	Transient Ischemic Events	121
	Transient Global Amnesia (TGA)	122
	Movement Disorders	122
	Sleep Disorders	123
	Psychogenic Nonepileptic Seizures (PNES)	124
	Autoimmune Neurologic Disorders Associated with Epilepsy	125
	Conclusion	126
	References	127
9	Sleep, Sleep Disorders, and Epilepsy	133
	<i>Diego Z. Carvalho, J. Layne Moore and Erik K. St. Louis</i>	
	Background/Introduction	133
	Epidemiology of Sleep-Related Seizures and Epilepsies	134
	Sleep and Circadian Physiology for the Epileptologist	134
	Pathophysiology and Mechanisms of Sleep-Related Interictal Epileptiform Discharges and Seizures, and Epileptic Perturbation of the Sleep State	136
	Common Sleep-Related Epilepsies	137
	Diagnostic Approach and Treatment of Sleep-Related Epilepsies	139
	Differential Diagnosis of Other Common Nocturnal Events and Mimickers of Sleep-Related Epilepsies	140
	Diagnosis and Treatment of Sleep Comorbidities in Epilepsy: Obstructive Sleep Apnea, Insomnia, and Restless Legs Syndrome	140
	Sleep and Risk of Sudden Unexpected Death in Epilepsy (SUDEP)	142
	Conclusions	142
	References	143

Epilepsy Journey: Identification of a Genetic Etiology for Epilepsy 147*Anthony L. Fine, Lily C. Wong-Kissel and Raj D. Sheth*

Patient Case 147

References 151

Epilepsy Journey 2: Evaluation of Spells in Adults 153*David B. Burkholder*

Case 1 153

Case 2 155

Case 3 155

Case 4 155

Case 5 156

Epilepsy Journey 3: The Pediatric Patient with Spells: Recommendations for Evaluation 157*Katherine C. Nickels and Elaine C. Wirrell*

Is the Event Due to a Seizure and Is It Likely to Recur? 157

If the Event Was Not Felt to be Seizure-Related, What Type of Non-epileptic Event Was It? 159

If the Event Was Felt to be Seizure-Related, What Type of Seizure Was it and Is the Event Part of an Epilepsy Electro-Clinical Syndrome? 161

References 161

Epilepsy Journey 4: Transitioning from Pediatric to Adult Epilepsy Clinic 165*Gregory D. Cascino, Katherine C. Nickels and Elaine C. Wirrell*

What Is Transition? 165

References 168

Section II Epilepsy: Treatment of Epilepsy: Non-Surgical Therapy 169**10 First Seizure 171***Scott Spritzer and Omar Danoun*

Background and Epidemiology of First-Time Seizures 171

Causes of Acute Symptomatic Seizures 172

Evaluation of a First Seizure 173

Treatment after a First Seizure 174

Summary 175

References 175

11 Antiseizure Medication Therapy 179*Kiran M. Kanth, Sarah Clark and Jeffrey W. Britton*

Introduction 179

ASM Selection 179

Seizure Type	179
Pharmacokinetics and ASM Selection	180
Mechanism of Action	183
Comorbidities	183
Side-Effect Profile	183
Drug–Drug Interactions	183
Titration Regimens	183
Cost of ASM	183
The ASMs: Summary of Clinical Use, Pharmacokinetics, and Efficacy	189
Brivaracetam	194
Indications, Usage, and Potential Side Effects	194
Dosage, Pharmacokinetics, and Potential Interactions	194
Carbamazepine	194
Indications, Usage, and Potential Side Effects	194
Dosage, Pharmacokinetics, and Potential Interactions	194
Clonazepam	195
Indications, Usage, and Potential Side Effects	195
Dosage, Pharmacokinetics, and Potential Interactions	195
Divalproex Sodium (Valproic Acid, Valproate)	195
Indications, Usage, and Potential Side Effects	195
Dosage, Pharmacokinetics, and Potential Interactions	196
Eslicarbazepine Acetate	196
Indications, Usage, and Potential Side Effects	196
Dosage, Pharmacokinetics, and Potential Interactions	196
Ethosuximide	196
Indications, Usage, and Potential Side Effects	196
Dosage, Pharmacokinetics, and Potential Interactions	197
Gabapentin	197
Indications, Usage, and Potential Side Effects	197
Dosage, Pharmacokinetics, and Potential Interactions	197
Efficacy	197
Lacosamide	198
Indications, Usage, and Potential Side Effects	198
Dosage, Pharmacokinetics, and Potential Interactions	198
Efficacy	198
Lamotrigine	198
Indications, Usage, and Potential Side Effects	198
Dosage, Pharmacokinetics, and Potential Interactions	199
Efficacy	199
Levetiracetam	199
Indications, Usage, and Potential Side Effects	199
Dosage, Pharmacokinetics, and Potential Interactions	200
Efficacy	200
Oxcarbazepine	200
Indications, Usage, and Potential Side Effects	200

Dosage, Pharmacokinetics, and Potential Interactions	200
Efficacy	201
Perampanel	201
Indications, Usage, and Potential Side Effects	201
Dosage, Pharmacokinetics, and Potential Interactions	201
Phenytoin	201
Indications, Usage, and Potential Side Effects	201
Dosage, Pharmacokinetics, and Potential Interactions	202
Phenobarbital	202
Indications, Usage, and Potential Side Effects	202
Dosage, Pharmacokinetics, and Potential Interactions	202
Primidone	203
Indications, Usage, and Potential Side Effects	203
Dosage, Pharmacokinetics, and Potential Interactions	203
Pregabalin	203
Indications, Usage, and Potential Side Effects	203
Dosage, Pharmacokinetics, and Potential Interactions	203
Efficacy	204
Tiagabine	204
Indications, Usage, and Potential Side Effects	204
Dosage, Pharmacokinetics, and Potential Interactions	204
Efficacy	204
Topiramate	204
Indications, Usage, and Potential Side Effects	204
Dosage, Pharmacokinetics, and Potential Interactions	205
Efficacy	205
Zonisamide	205
Indications, Usage, and Potential Side Effects	205
Dosage, Pcal Interactions	205
Efficacy	206
Subspecialty ASMs	206
Cannabidiol	206
Indications, Usage, and Potential Side Effects	206
Clobazam	207
Felbamate	207
Rufinamide	208
Stiripentol	208
Vigabatrin	209
References	210

12 **Epilepsy in Women** 217

Katherine Noe

Introduction 217

Hormonal Influences on Epilepsy 217

Reproductive Health in Women with Epilepsy 219

	Reproductive Dysfunction	219
	Pregnancy in Women with Epilepsy	220
	Birth Defects	220
	Seizure Control	222
	Safety	222
	Breast Feeding	223
	Contraception for Women on Antiepileptic Medication	223
	Menopause in Women with Epilepsy	224
	References	224
13	Treating Children with Epilepsy: Antiepileptic Medications (AEDs)	229
	<i>Raj D. Sheth</i>	
	Introduction	229
	Initial Unprovoked Seizure	230
	AED Selection	230
	Monotherapy over Polytherapy where Possible	230
	Consideration of Formulation and Pharmacokinetics	230
	Puberty and AED Selectin	231
	Oral Contraceptives and Pregnancies	231
	Adverse Effects	232
	Screening Labs	232
	AEDs in Pediatric Epilepsy	232
	Valproate	232
	Ethosuximide	233
	Levetiracetam	233
	Clobazam	234
	Lamotrigine	234
	Perampanel	235
	Vigabatrin	235
	Adrenocorticotropin (ACTH)	236
	Adherence to AED Therapy	236
	AEDs for Sport Participation and Driving	237
	References	237
14	Dietary Therapy in Epilepsy	239
	<i>Katherine C. Nickels and Elaine C. Wirrell</i>	
	Introduction	239
	Mechanism of Action	239
	Formulations of the Ketogenic Diet	240
	Classical	240
	Medium-Chain Triglyceride (MCT) Diet	240
	Modified Atkins Diet (MAD)	240
	Low Glycemic Index Treatment (LGIT) Diet	240
	Indications for Dietary Therapy	241
	Starting the Diet	242

	Pre-Diet Counseling and Testing	242
	Initiating the Diet	242
	Supplements	243
	Management of Concurrent Medications	243
	Safety and Monitoring for Adverse Effects	244
	Efficacy Data	245
	Weaning the Ketogenic Diet	245
	Conclusions	246
	References	246
15	Autoimmune Epilepsy Disorders	249
	<i>Jeffrey W. Britton, Eoin P. Flanagan, Andrew McKeon and Sean J. Pittock</i>	
	Epidemiology	249
	Etiologies and Mechanisms	250
	Clinical Presentation	253
	Scoring Systems in the Evaluation and Treatment of Autoimmune Epilepsy	254
	Diagnostic Testing in Autoimmune Epilepsy	254
	EEG	254
	Serological Findings (Serum and CSF)	256
	Neuroimaging	259
	Brain MRI	259
	18-Fluorodeoxyglucosae (FDG) – Positron Emission Tomography (PET)	259
	Imaging in Cancer Detection in Autoimmune Epilepsy	260
	Treatment	261
	Acute Treatment and General Approach	261
	Treatment of Specific Neural Antibody-Associated Encephalitides	266
	NMDA-R Antibody Encephalitis	266
	LGI1 Antibody Encephalitis	266
	Other Neural Antibodies	266
	Maintenance Immunosuppression	266
	Future Therapies	267
	Cancer Treatment	267
	Antiseizure Medication Therapy and Other Treatments	267
	Conclusion	268
	References	269
16	Discontinuation of Antiseizure Medication	275
	<i>Jamal F. Khattak and Jeffrey W. Britton</i>	
	Introduction	275
	Methodological Issues in Studies Evaluating ASM Discontinuance	276
	Seizure Recurrence Rates After ASM Discontinuance	276
	Factors that Predict Seizure Recurrence After ASM Discontinuance	277
	Age, Duration, and Timing	277
	Epilepsy Syndromes and Etiology	278
	Seizure Characteristics	279

	Other Demographic and Clinical Factors	279
	Antiseizure Medication Use	279
	Role of Electroencephalogram (EEG)	279
	Risk-Prediction Models	280
	Practical Considerations of ASM Discontinuance	282
	References	283
17	Investigational Therapy and Drug Approval Process within the US and Cannabidiol	287
	<i>Gregory Sprout, Joseph I. Sirven and Gregory D. Cascino</i>	
	Introduction	287
	US Food and Drug Administration	288
	Pharmaceutical Development and Approval Process	289
	Five Stages	289
	Discovery and Development	289
	Pre-Clinical Research	290
	Clinical Research	290
	FDA Review	292
	FDA Action and Post-Approval Risk Assessment	293
	Expedited Approval Tracks for Pharmaceutical Therapies	293
	Fast Track	293
	Breakthrough Therapy	293
	Accelerated Approval	295
	Priority Review	295
	Generic Drugs	295
	Medical Device Development and Approval Process	296
	Cannabidiol for Epilepsy	297
	Government's Role in Regulation	298
	Current Pipeline, Futuristic Therapies, and the Regulatory Implications	298
	References	299
18	Devices to Monitor and Track Your Epilepsy	301
	<i>Nicholas M. Gregg and Amy Z. Crepeau</i>	
	Introduction	301
	Generators and Origins of Biosignals	302
	EEG Based Sensors (Scalp, Sub-Scalp, Intracranial)	302
	Scalp EEG	302
	Subcutaneous EEG	302
	Intracranial EEG	303
	Extracerebral Sensors	303
	Accelerometry/Gyroscopes/Magnetometers	303
	Electrodermal Activity (EDA)	303
	Surface Electromyography (EMG)	304

Cardiac and Respiratory Monitors	304
Photoplethysmography (PPG)	304
Electrocardiography (ECG)	304
Respiratory Effort Belt	304
Temperature Sensors	304
Mattress Sensors	305
Video and Radar-Based Devices	305
Seizure Dogs	305
Patient Self-Reported Seizure Diaries	305
Multimodal Detection Devices	305
Sensitivity, Specificity, False-Alarm Rates, and Receiver Operating Characteristic Curves	306
Seizure Detection for Different Types of Seizures	306
Commercially Available Devices	307
Cost	308
Conclusions	308
References	309

Epilepsy Journey 5: Seizure Emergencies (Include status Epilepticus, Fires, Norse, Seizure First Aid, and Seizure Clusters)

Anteneh M. Feyissa, Matthew T. Hoerth and Eric T. Payne

Epilepsy Journey 6: The First seizure – How to Evaluate: Pediatric

Korwyn Williams

References 316

Epilepsy Journey 7: The First Seizure – How to Evaluate: Adult

Paul M. Magtibay and Joseph I. Sirven

References 318

Epilepsy Journey 8: Treating Epilepsy Second Seizure and beyond: How to Choose a Drug – An Algorithm

Amy Z. Crepeau

References 322

Epilepsy Journey 9: Treating Status Epilepticus: An Algorithm

Sara E. Hocker and Eric T. Payne

Epilepsy Journey 10: Withdrawal of ASDs in Adults: An Algorithm

Sarah A. Merrill, Kent R. Richter and Joseph I. Sirven

Withdrawal of Anti-Seizure Drugs (ASDs) in Adults: A Treatment Algorithm 331

Timing of Anti-Seizure Drug Withdrawal 331

Timing and Rate of ASD Withdrawal 333

References 333

Epilepsy Journey 11: Withdrawal of ASDs in Seizure-Free Patients Children: The Pediatric Neurologist's Perspective 335

Elaine C. Wirrell

References 337

Epilepsy Journey 12: Withdrawing ASDs in Adults after Epilepsy Surgery 339

Christian Rosenow, Luca Farrugia, Andrew Pines and Joseph I. Sirven

References 341

Epilepsy Journey 13: The Pregnant Patient with Epilepsy: An Algorithm 343

Katherine Noe

Section III Epilepsy: Treatment of Epilepsy: Surgical Management 345

19 Pre-surgical Evaluation 347

David B. Burkholder, Anthony L. Ritaccio and Cheolsu Shin

Introduction 347

Patient Selection 347

Epilepsy Type 347

Drug Resistance 348

Misconceptions About Epilepsy Surgery 349

Patient Goals 349

Misconceptions About Who Is Appropriate for Surgery 350

Misunderstandings About Surgery and Outcomes 351

Diagnostic Evaluation 351

Primary Evaluation 351

Magnetic Resonance Imaging (MRI) 352

Epilepsy Monitoring and Seizure Classification 352

Neuropsychology Testing 353

Additional Evaluation 353

Single-Photon Emission Computed Tomography (SPECT) 354

Positron Emission Tomography 354

Magnetoencephalography 355

Electrical Source Imaging (ESI) 356

Intracarotid Amobarbital Procedure 356

Functional MRI 357

Surgically Remediable Epilepsy Syndromes 357

Mesial Temporal Lobe Epilepsy 357

Focal Cortical Dysplasia 358

Tuberous Sclerosis 360

Long-Term Epilepsy-Associated Tumors 361

Vascular Lesions 361

	Pediatric Hemispheric Epilepsy Syndromes	361
	Conclusion	361
	References	362
20	Minimally Invasive Epilepsy Surgery	367
	<i>Sanjeet S. Grewal, Robert E. Wharen Jr. and William O. Tatum</i>	
	Radiofrequency Thermoablation	367
	Stereotactic Radiosurgery (SRS)	369
	Laser Interstitial Thermal Therapy	371
	Mesial Temporal Lobe	372
	Specific Lesions	373
	Minimally Invasive Corpus Callosotomy	374
	Conclusion	374
	References	374
21	Intracranial EEG Monitoring	381
	<i>Jamie J. Van Gompel, Katherine Noe and Richard S. Zimmerman</i>	
	Introduction	381
	Identifying Candidates for Invasive EEG Monitoring	381
	Indications for Invasive EEG Monitoring	382
	Choosing an Implantation Strategy: Benefits and Risks	383
	Invasive EEG Using sEEG Electrodes: Technical Considerations	385
	Invasive EEG Using Subdural Electrodes	388
	Conclusion	398
	References	398
22	Surgical Strategies (Include Cortical Resection, Lesionectomy, Cortical Stimulation and Functional Mapping, Hemispherotomy)	401
	<i>Angela Bohnen, W. Richard Marsh, Alfredo Quinones-Hinojosa and Kaisorn L. Chaichana</i>	
	Introduction	401
	Surgical Procedures	402
	Lesionectomy	402
	Temporal Lobe Epilepsy	403
	Anterior Temporal Lobectomy (ATL)	403
	Selective Amygdalohippocampectomy	404
	Cortical Stimulation and Functional Mapping	405
	Hemispherotomy	406
	Complications	406
	Outcomes	407
	Seizure Control	407
	Quality of Life	407
	Cognition	408

Driving 408
 Timing of Surgery 408
 References 408

23 **Corpus Callosotomy** 413

Elaine C. Wirrell, Lily C. Wong-Kisiel and Kai J. Miller

Indications 413
 Surgical Techniques 414
 Evaluation of Callosotomy Extent 416
 Complications of Callosotomy 416
 Efficacy of Callosotomy 417
 Multiple Subpial Transection 418
 Efficacy of MST in Landau Kleffer Syndrome 418
 Efficacy of MST in Other Cases Involving Eloquent Cortex 418
 Efficacy of Multiple Hippocampal Transection in Temporal
 Lobe Epilepsy 419
 Hemispherectomy 419
 Pre-surgical Evaluations 419
 Surgical Techniques 420
 Complications 422
 Seizure Outcome / Efficacy 424
 Global Functional Outcome 425
 Surgical Failures/Re-Operations 426
 Conclusion 426
 References 426

24 **Neuromodulation for Epilepsy** 431

Brian N. Lundstrom, Robert E. Wharen, Jr and William O. Tatum

Introduction 431
 Historical Context 431
 Stimulation Approaches of VNS, RNS, and DBS 432
 Efficacy and Safety of VNS, RNS, and DBS 433
 Application of Stimulation Approaches and Other Considerations 435
 References 437

25 **Emerging Treatments for Epilepsy** 441

Gregory A. Worrell, Benjamin H. Brinkmann, Brian N. Lundstrom and Matt Stead

Introduction 441
 Next-Generation Epilepsy Biomarker Discovery and Management
 System 443
 Pre-Clinical Testing of Next-Gen Epilepsy Management System in Canine
 Epilepsy 444
 Ethical Considerations 445
 Conclusions 446
 Acknowledgement 446
 References 446

26 **Seizure Forecasting in Epilepsy: From Computation to Clinical Practice** 451

Benjamin H. Brinkmann, Nicholas M. Gregg and Gregory A. Worrell

Introduction 451

Computational and Data Resources 452

Devices and Ambulatory Monitoring 453

New Devices and Ongoing Efforts 454

Summary 456

References 457

Epilepsy Journey 14: The Drug-Resistant Patient: Pre-surgical Evaluation and Surgery-Approach to the “Skip” Candidate 463

Anteneh M. Feyissa and David B. Burkholder

Discussion 465

References 468

Epilepsy Journey 15: The Drug-Resistant Patient and Discordant Pre-surgical Evaluation 469

Lily C. Wong-Kiesel, Elson L. So and Richard S. Zimmerman

Case 1 469

Case 2 471

Discussion 472

References 475

Epilepsy Journey 16: The Drug-Resistant Patient who is not a Candidate for Resective Surgery: An Approach to Neuromodulation 477

Anthony L. Ritaccio and William O. Tatum

Introduction 477

Case Discussion 477

Conclusion 480

References 482

Epilepsy Journey 17: Epilepsy Surgery in Pediatric Patients 483

Raj D. Sheth, Kai J. Miller and Elaine C. Wirrell

Pre-surgical Evaluation: Antiseizure Drugs (ASDs) 484

Seizure Semiology 485

Identification of Drug-resistant Epilepsy 485

EEG and Epilepsy Monitoring Unit (EMU) planning 486

Epilepsy Pre-Surgical Conference 487

Intracranial EEG Monitoring 487

Surgical Treatment of Neocortical Focal Epilepsy 488

Hemispheric Epilepsy 488

Drug-resistant Generalized Epilepsy and Non-localized Focal Epilepsy 489

References 489

Index 491

